Viral DNA-dependent induction of innate immune response to hepatitis B virus in immortalized mouse hepatocytes

Journal of Virology

Volumn 90, Issue 1, 2016, Pages 486-496

  Cui, Xiuji ^a   Clark, Daniel N ^a   Liu, Kuancheng ^a   Xu, Xiao Dong ^b   Guo, Ju Tao ^b   Hu, Jianming ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b BARUCH S BLUMBERG INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; CIRCULAR DNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOPLASM; DNA SYNTHESIS INHIBITION; GENE EXPRESSION; GENE REPLICATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMORTALIZED CELL LINE; INNATE IMMUNITY; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE; ANIMAL; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

ANIMALS; CELL LINE; CYTOPLASM; DNA, CIRCULAR; DNA, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HEPATITIS B VIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; IMMUNITY, INNATE; MICE; VIRUS REPLICATION;

EID: 84953924182     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01263-15     Document Type: Article

References (65)

1. Seeger C, Zoulim F, Mason WS. 2013. Hepadnaviruses, p 2185-2221. In Knipe DM, Howley PM (ed), Fields virology. Lippincott, Williams & Wilkins, Philadelphia, PA.
2. Mason WS, Halpern MS, England JM, Seal G, Egan J, Coates L, Aldrich C, Summers J. 1983. Experimental transmission of duck hepatitis B virus. Virology 131:375-384. http://dx.doi.org/10.1016/0042-6822(83)90505-6.
3. Miller RH, Robinson WS. 1984. Hepatitis B virus DNA forms in nuclear and cytoplasmic fractions of infected human liver. Virology 137:390-399. http://dx.doi.org/10.1016/0042-6822(84)90231-9.
4. Summers J, Mason WS. 1982. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29:403-415. http://dx.doi.org/10.1016/0092-8674(82)90157-X.
5. Hu J, Seeger C. 2015. Hepadnavirus genome replication and persistence. Cold Spring Harb Perspect Med 5:a021386. http://dx.doi.org/10.1101/cshperspect.a021386.
6. Tuttleman JS, Pourcel C, Summers J. 1986. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47:451-460. http://dx.doi.org/10.1016/0092-8674(86)90602-1.
7. Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. 1990. In hepa-tocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 175:255-261. http://dx.doi.org/10.1016/0042-6822(90)90206-7.
8. Gao W, Hu J. 2007. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol 81:6164-6174. http://dx.doi.org/10.1128/JVI.02721-06.
9. Cui X, Ludgate L, Ning X, Hu J. 2013. Maturation-associated destabilization of hepatitis B virus nucleocapsid. J Virol 87:11494-11503. http://dx.doi.org/10.1128/JVI.01912-13.
10. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373-384. http://dx.doi.org/10.1038/ni.1863.
11. Paludan SR, Bowie AG. 2013. Immune sensing of DNA. Immunity 38: 870-880. http://dx.doi.org/10.1016/j.immuni.2013.05.004.
12. Gao D, Wu J, Wu YT, Du F, Aroh C, Yan N, Sun L, Chen ZJ. 2013. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 341:903-906. http://dx.doi.org/10.1126/science.1240933.
13. Sun L, Wu J, Du F, Chen X, Chen ZJ. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339:786-791. http://dx.doi.org/10.1126/science.1232458.
14. Cai X, Chiu YH, Chen ZJ. 2014. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 54:289-296. http://dx.doi.org/10.1016/j.molcel.2014.03.040.
15. Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G, Krogan NJ, Greene WC. 2014. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science 343:428-432. http://dx.doi.org/10.1126/science.1243640.
16. Kerur N, Veettil MV, Sharma-Walia N, Bottero V, Sadagopan S, Otageri P, Chandran B. 2011. IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection. Cell Host Microbe 9:363-375. http://dx.doi.org/10.1016/j.chom.2011.04.008.
17. Burdette DL, Vance RE. 2013. STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol 14:19-26. http://dx.doi.org/10.1038/ni.2491.
18. Tanaka Y, Chen ZJ. 2012. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal 5:ra20. http://dx.doi.org/10.1126/scisignal.2002521.
19. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, Dusheiko GM, Jacobs M, Klenerman P, Maini MK. 2009. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137: 1289-1300. http://dx.doi.org/10.1053/j.gastro.2009.06.054.
20. Wieland S, Thimme R, Purcell RH, Chisari FV. 2004. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 101:6669-6674. http://dx.doi.org/10.1073/pnas.0401771101.
21. Wieland SF, Spangenberg HC, Thimme R, Purcell RH, Chisari FV. 2004. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A 101:2129-2134. http://dx.doi.org/10.1073/pnas.0308478100.
22. Fletcher SP, Chin DJ, Cheng DT, Ravindran P, Bitter H, Gruenbaum L, Cote PJ, Ma H, Klumpp K, Menne S. 2013. Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B. Hepatology 57:13-22. http://dx.doi.org/10.1002/hep.25954.
23. Fletcher SP, Chin DJ, Ji Y, Iniguez AL, Taillon B, Swinney DC, Ravindran P, Cheng DT, Bitter H, Lopatin U, Ma H, Klumpp K, Menne S. 2012. Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology 56:820-830. http://dx.doi.org/10.1002/hep.25730.
24. Wieland SF, Asabe S, Engle RE, Purcell RH, Chisari FV. 2014. Limited hepatitis B virus replication space in the chronically hepatitis C virus-infected liver. J Virol 88:5184-5188. http://dx.doi.org/10.1128/JVI.03553-13.
25. Chang J, Block TM, Guo JT. 2012. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res 96:405-413. http://dx.doi.org/10.1016/j.antiviral.2012.10.001.
26. Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, Zoulim F. 2010. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 51:63-72. http://dx.doi.org/10.1002/hep.23230.
27. Hosel M, QuasdorffM, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, Langenkamp A, Falk C, Buning H, Rose-John S, Protzer U. 2009. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50:1773-1782. http://dx.doi.org/10.1002/hep.23226.
28. Shlomai A, Schwartz RE, Ramanan V, Bhatta A, de Jong YP, Bhatia SN, Rice CM. 2014. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci U S A 111:12193-12198. http://dx.doi.org/10.1073/pnas.1412631111.
29. Chisari FV, Ferrari C. 1995. Hepatitis B virus immunopathology. Springer Semin Immunopathol 17:261-281.
30. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829. http://dx.doi.org/10.1126/science.284.5415.825.
31. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV. 2005. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A 102:9913-9917. http://dx.doi.org/10.1073/pnas.0504273102.
32. Heise T, Guidotti LG, Chisari FV. 2001. Characterization of nuclear RNases that cleave hepatitis B virus RNA near the La protein binding site. J Virol 75:6874-6883. http://dx.doi.org/10.1128/JVI.75.15.6874-6883.2001.
33. Guidotti LG, Chisari FV. 2001. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19:65-91. http://dx.doi.org/10.1146/annurev.immunol.19.1.65.
34. Uprichard SL, Wieland SF, Althage A, Chisari FV. 2003. Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci U S A 100:1310-1315. http://dx.doi.org/10.1073/pnas.252773599.
35. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M. 2012. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 122:529-537. http://dx.doi.org/10.1172/JCI58847.
36. Guo H, Jiang D, Ma D, Chang J, Dougherty AM, Cuconati A, Block TM, Guo JT. 2009. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 83:847-858. http://dx.doi.org/10.1128/JVI.02008-08.
37. Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, Li S, Li W, Block TM, Chang J, Guo JT. 2013. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog 9:e1003613. http://dx.doi.org/10.1371/journal.ppat.1003613.
38. Tian Y, Chen WL, Ou JH. 2011. Effects of interferon-alpha/beta on HBV replication determined by viral load. PLoS Pathog 7:e1002159. http://dx.doi.org/10.1371/journal.ppat.1002159.
39. Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X, Wei L, Chang J, Block TM, Guo JT. 2010. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol 84:9332-9340. http://dx.doi.org/10.1128/JVI.00918-10.
40. Guidotti LG, Matzke B, Schaller H, Chisari FV. 1995. High-level hepatitis B virus replication in transgenic mice. J Virol 69:6158-6169.
41. Cui X, Guo JT, Hu J. 2015. Hepatitis B virus covalently closed circular DNA formation in immortalized mouse hepatocytes associated with nucleocapsid destabilization. J Virol 89:9021-9028. http://dx.doi.org/10.1128/JVI.01261-15.
42. Wu JC, Merlino G, Fausto N. 1994. Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci U S A 91:674-678. http://dx.doi.org/10.1073/pnas.91.2.674.
43. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 41:1715-1720.
44. Jiao L, Liang Y, Xu J. 2006. Origin of the relative stereoselectivity of the beta-lactam formation in the Staudinger reaction. J Am Chem Soc 128: 6060-6069. http://dx.doi.org/10.1021/ja056711k.
45. Hu J, Flores D, Toft D, Wang X, Nguyen D. 2004. Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J Virol 78:13122-13131. http://dx.doi.org/10.1128/JVI.78.23.13122-13131.2004.
46. Liu K, Ludgate L, Yuan Z, Hu J. 2015. Regulation of multiple stages of hepadnavirus replication by the carboxyl-terminal domain of viral core protein in trans. J Virol 89:2918-2930. http://dx.doi.org/10.1128/JVI.03116-14.
47. Ning X, Nguyen D, Mentzer L, Adams C, Lee H, Ashley R, Hafenstein S, Hu J. 2011. Secretion of genome-free hepatitis B virus-single strand blocking model for virion morphogenesis of para-retrovirus. PLoS Pathog 7:e1002255. http://dx.doi.org/10.1371/journal.ppat.1002255.
48. Scaglione SJ, Lok AS. 2012. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 142:1360-1368 e1361. http://dx.doi.org/10.1053/j.gastro.2012.01.044.
49. King RW, Ladner SK, Miller TJ, Zaifert K, Perni RB, Conway SC, Otto MJ. 1998. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother 42:3179-3186.
50. Helgason E, Phung QT, Dueber EC. 2013. Recent insights into the complexity of Tank-binding kinase 1 signaling networks: the emerging role of cellular localization in the activation and substrate specificity of TBK1. FEBS Lett 587:1230-1237. http://dx.doi.org/10.1016/j.febslet.2013.01.059.
51. Deres K, Schroder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Kramer T, Niewohner U, Pleiss U, Stoltefuss J, Graef E, Koletzki D, Masantschek RN, Reimann A, Jaeger R, Gross R, Beckermann B, Schlemmer KH, Haebich D, Rubsamen-Waigmann H. 2003. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299:893-896. http://dx.doi.org/10.1126/science.1077215.
52. Stein SC, Lam E, Falck-Pedersen E. 2012. Cell-specific regulation of nucleic acid sensor cascades: a controlling interest in the antiviral response. J Virol 86:13303-13312. http://dx.doi.org/10.1128/JVI.02296-12.
53. Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV. 2002. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 76:5646-5653. http://dx.doi.org/10.1128/JVI.76.11.5646-5653.2002.
54. Schoggins JW, MacDuffDA, Imanaka N, Gainey MD, Shrestha B, Eitson JL, Mar KB, Richardson RB, Ratushny AV, Litvak V, Dabelic R, Manicassamy B, Aitchison JD, Aderem A, Elliott RM, Garcia-Sastre A, Racaniello V, Snijder EJ, Yokoyama WM, Diamond MS, Virgin HW, Rice CM. 2014. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505:691-695. http://dx.doi.org/10.1038/nature12862.
55. Qiao M, Scougall CA, Duszynski A, Burrell CJ. 1999. Kinetics of early molecular events in duck hepatitis B virus replication in primary duck hepatocytes. J Gen Virol 80:2127-2135. http://dx.doi.org/10.1099/0022-1317-80-8-2127.
56. Rabe B, Vlachou A, Pante N, Helenius A, Kann M. 2003. Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci U S A 100:9849-9854. http://dx.doi.org/10.1073/pnas.1730940100.
57. Cui X, Luckenbaugh L, Bruss V, Hu J. 2015. Alteration of mature nucleocapsid and enhancement of covalently closed circular DNA formation by hepatitis B virus core mutants defective in complete virion formation. J Virol 89:10064-10072. http://dx.doi.org/10.1128/JVI.01481-15.
58. Chatzinikolaou G, Karakasilioti I, Garinis GA. 2014. DNA damage and innate immunity: links and trade-offs. Trends Immunol 35:429-435. http://dx.doi.org/10.1016/j.it.2014.06.003.
59. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Orlandini A, Sacchelli L, Missale G, Ferrari C. 2009. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58:974-982. http://dx.doi.org/10.1136/gut.2008.163600.
60. Vanwolleghem T, Hou J, van Oord G, Andeweg AC, Osterhaus AD, Pas SD, Janssen HL, Boonstra A. 2015. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. Hepatology 62:87-100. http://dx.doi.org/10.1002/hep.27805.
61. Lutgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann JH, Pollok JM, Lohse AW, Petersen J, Dandri M. 2011. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 140:2074-2083. http://dx.doi.org/10.1053/j.gastro.2011.02.057.
62. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, Hornung V, Vogel SN, Szomolanyi-Tsuda E, Fitzgerald KA. 2010. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 11:395-402. http://dx.doi.org/10.1038/ni.1864.
63. Liaw YF. 2013. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy. J Hepatol 59:880-881. http://dx.doi.org/10.1016/j.jhep.2013.05.007.
64. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. 2013. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58:98-107. http://dx.doi.org/10.1002/hep.26180.
65. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, REVEAL-HBV Study Group. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73. http://dx.doi.org/10.1001/jama.295.1.65.